Skip to main content

Page of 2 next disabled
and
  1. No Access

    Chapter

    Bioengineered Vascularized Insulin Producing Endocrine Tissues

    Islet transplantation is a promising treatment for type 1 diabetes (T1D), but limited islet engraftment hampers its success. In vivo, islets require time to remodel the hepatic parenchyma and establish their o...

    Francesco Campo, Alessia Neroni in Pluripotent Stem Cell Therapy for Diabetes (2023)

  2. No Access

    Chapter

    Safety Issues Related to Pluripotent Stem Cell-Based Therapies: Tumour Risk

    As the exciting era of regenerative medicine has dawned, considerable efforts aim to further develop human pluripotent stem cell (hPSC)-based therapies for a plethora of diseases, including diabetes mellitus. ...

    Sanne Hillenius, Joaquin Montilla-Rojo in Pluripotent Stem Cell Therapy for Diabetes (2023)

  3. No Access

    Chapter

    Minimal SC-β-Cell Properties for Transplantation in Diabetic Patients

    Pancreatic β cells within the islets of Langerhans are the body’s main source for insulin. β cells maintain glucose homeostasis through the tight control of insulin secretion and cessation in response to chang...

    Veronica Cochrane, Yini **ao, Hasna Maachi in Pluripotent Stem Cell Therapy for Diabetes (2023)

  4. No Access

    Chapter

    Modelling of Beta Cell Pathophysiology Using Stem Cell-Derived Islets

    Diabetes mellitus is a family of metabolic disorders that arise from the loss or dysfunction of insulin secreting pancreatic beta cells. Many forms of early onset diabetes are caused by monogenic mutations in ...

    Tom Barsby, Hossam Montaser, Väinö Lithovius in Pluripotent Stem Cell Therapy for Diabetes (2023)

Page of 2 next disabled